IDEAL2
Research type
Research Study
Full title
An Open-Label, Single Dose, Multi-Site, Phase 2b Trial to Assess the Imaging Performance of [18F]AldoView Positron Emission Tomography (PET) in Participants With and Without Primary Aldosteronism
IRAS ID
1013308
Contact name
Bryan Williams
Contact email
Sponsor organisation
University College London (UCL)
ISRCTN Number
ISRCTN15647953
Research summary
High blood pressure is extremely common, and one important but often overlooked cause is Primary Aldosteronism (PA). PA occurs when adrenal glands produce too much of the hormone aldosterone which helps control the balance of sodium and potassium in the body. When aldosterone is overproduced, the body keeps too much sodium and water, leading to raised blood pressure, and loss of potassium. PA is treatable if doctors can identify the adrenal gland responsible.
The challenge is that the abnormal areas within the adrenal glands that produce excess aldosterone can be very small, making them difficult to detect using current tests. The standard test, Adrenal Vein Sampling (AVS) is invasive, technically complex and not always successful. Existing Positron Emission Tomography / Computed Tomography (PET/CT) scans have also been limited because older radiotracers could not reliably identify very small abnormalities.
This study will test AldoView, a new radiotracer designed to show areas of increased enzyme activity involved in aldosterone production. A radiotracer is a substance linked to a very small amount of radioactivity that allows doctors to see how organs function. When AldoView is injected, it highlights adrenal gland activity on a PET/CT scan.
The aim of the study is to find out whether AldoView can more accurately identify which adrenal gland is overactive, helping doctors decide whether surgery will be of benefit to the patient. We will recruit three groups: patients with PA, patients with other adrenal conditions, and patients without adrenal conditions (i.e. healthy volunteers). Participants will attend an imaging department at an NHS centre experienced in adrenal imaging, receive an injection of AldoView and undergo a PET/CT scan. Early research in 17 patients showed good results, good tolerability and no significant side effects. If successful, AldoView may provide a faster, safer, more accurate way to diagnose PA and guide treatment.
REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
26/LO/0207
Date of REC Opinion
13 Apr 2026
REC opinion
Further Information Favourable Opinion